Pesquisadores ligados à Tel Aviv University, de Israel, ao Centers for Disease Control and Prevention e à Emory University School of Medicine, de Atlanta, publicaram, recentemente, no The New England Journal of Medicine, um estudo em que procuraram avaliar a magnitude da não prevenção de malária tardia em viajantes, tratados com esquizonticidas sangüíneos.
Foram analisados dados de vigilância epidemiológica quanto à malária em Israel e nos Estados Unidos e determinou-se o destino dos viajantes, as espécies infectantes de malária, o tipo de quimioprofilaxia utilizada e o período de incubação.
Em Israel, entre 1994 e 1999, houve 300 casos de malária em pacientes retornando de viagem, com identificação das espécies de Plasmodium envolvidas. Em 134 casos (44,7%), a doença desenvolveu-se após duas ou mais semanas do retorno do paciente, e em quase todos os casos, isolou-se Plasmodium vivax ou P. ovale. Dos 134 casos, 108 indivíduos (80,6%) utilizaram esquema antimalárico de acordo com as diretrizes nacionais.
Nos Estados Unidos, entre 1992 e 1998, houve 2 822 casos de malária, sendo que ocorreu desenvolvimento de malária tardia em 987 pacientes (35%). A infecção foi causada por P. vivax em 811 indivíduos, por P. ovale em 66 pacientes, por P. falciparum em 59 indivíduos e por P. malariae em 51 pacientes. Seiscentos e quatorze indivíduos com malária de desenvolvimento tardio utilizaram agentes antimaláricos eficazes.
Os pesquisadores concluíram que a maioria dos casos de malária de surgimento tardio não é evitada pelo uso de agentes esquizonticidas sangüíneos eficazes e comumente utilizados.
Delayed Onset of Malaria - Implications for Chemoprophylaxis in Travelers - The New England Journal of Medicine
Delayed Onset of Malaria — Implications for Chemoprophylaxis in Travelers
Eli Schwartz, M.D., Monica Parise, M.D., Phyllis Kozarsky, M.D., and Martin Cetron, M.D.
ABSTRACT
Background Most antimalarial agents used by travelers act on the parasite's blood stage and therefore do not prevent late-onset illness, particularly that due to species that cause relapsing malaria. We examined the magnitude of this problem among Israeli and American travelers.
Methods We examined malaria surveillance data from Israel and the United States to determine the traveler's destination, the infecting species, the type of chemoprophylaxis used, and the incubation period.
Results In Israel, from 1994 through 1999, there were 300 cases of malaria among returning travelers in which one species of plasmodium could be identified. In 134 of these cases (44.7 percent), the illness developed more than two months after the traveler's return; nearly all of these cases were due to infection with Plasmodium vivax or P. ovale. In 108 of the 134 cases (80.6 percent), the patient had used an antimalarial regimen according to national guidelines. In the United States, from 1992 through 1998, there were 2822 cases of malaria among travelers in which the cause could be evaluated. Late illness developed in 987 (35.0 percent) of these travelers. The infection was due to P. vivax in 811 travelers, P. ovale in 66, P. falciparum in 59, and P. malariae in 51; 614 (62.2 percent) of those with late-onset illness had appropriately taken an effective antimalarial agent.
Conclusions In more than one third of malaria-infected travelers, the illness developed more than two months after their return. Most of these late-onset illnesses are not prevented by the commonly used and effective blood schizonticides. Agents that act on the liver phase of malaria parasites are needed for more effective prevention of malaria in travelers.
Source Information
From the Center for Geographical Medicine and the Department of Medicine, C. Chaim Sheba Medical Center, Tel Hashomer, and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (E.S.); and the Malaria Epidemiology Branch, Division of Parasitic Diseases (M.P.), and the Surveillance and Epidemiology Branch, Division of Global Migration and Quarantine (M.C.), National Center for Infectious Diseases, Centers for Disease Control and Prevention; the Public Health Service, Department of Health and Human Services (M.P., M.C.); and the Department of Medicine, Emory University School of Medicine (P.K.) — all in Atlanta.
Address reprint requests to Dr. Schwartz at the Center for Geographical Medicine and the Department of Medicine, C. Chaim Sheba Medical Center, Tel Hashomer 52621, Israel, or at elischwa@post.tau.ac.il.
